CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J.
Right arrow Articles by Schofield, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J.
Right arrow Articles by Schofield, P. N.

Cell Growth & Differentiation, Vol 8, Issue 8 927-934, Copyright © 1997 by American Association of Cancer Research


ARTICLES

Stable integration of an mdx skeletal muscle cell line into dystrophic (mdx) skeletal muscle: evidence for stem cell status

J Smith and PN Schofield
Department of Anatomy, University of Cambridge, United Kingdom. JS10046@cam.ac.uk

We have previously described a method for the derivation of long term cultures of undifferentiated myoblasts from the skeletal muscle of dystrophic (mdx) mice (J. Smith and P. N. Schofield, Exp. Cell Res., 210: 86-93, 1994). We now show that a clonal mdx-derived skeletal muscle cell line labeled with a retrovirus conferring beta-galactosidase activity and G418 resistance (PD50A) is capable of incorporation into mdx skeletal muscle myofibers for up to 14 months with no incidence of tumor formation. After a lag period of 5 days, injected PD50A cells disperse throughout the injected tibialis anterior muscle and take up satellite cell positions on the perimeter of myofiber bundles. PD50A cells begin to incorporate into fused muscle syncitium as early as 8 weeks after injection and persist for at least 14 months. We have rederived myoblasts expressing beta-galactosidase from PD50A-injected muscles 12 months after injection, demonstrating that a reserve of mononuclear proliferation-competent PD50A cells are present in host muscle up to a year after their original introduction. These data support the contention that myoblasts derived by this culture method are functionally representative of a class of skeletal muscle "stem cells" and thus have potential both as agents for cellular therapy of intransigent diseases such as Duchenne muscular dystrophy as well as being a useful tool for the further investigation of normal muscle development.


This article has been cited by other articles:


Home page
DMMHome page
D. Merrick, L. K. J. Stadler, D. Larner, and J. Smith
Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation
Dis. Model. Mech., July 1, 2009; 2(7-8): 374 - 388.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
S. B. P. CHARGE and M. A. RUDNICKI
Cellular and Molecular Regulation of Muscle Regeneration
Physiol Rev, January 1, 2004; 84(1): 209 - 238.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
Z. Qu-Petersen, B. Deasy, R. Jankowski, M. Ikezawa, J. Cummins, R. Pruchnic, J. Mytinger, B. Cao, C. Gates, A. Wernig, et al.
Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration
J. Cell Biol., May 28, 2002; 157(5): 851 - 864.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1997 by the American Association of Cancer Research.